Navigation Links
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
Date:3/30/2009

RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels.

For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. Seventeen subjects were healthy; the other 17 were at high risk for developing lifestyle-related illnesses.

Both groups had a decrease in body fat percentage and total serum cholesterol. However, the high-risk group also experienced lowered blood glucose, possibly due to improved insulin sensitivity induced by adding Chlorella to the daily diet.

Heart disease and stroke are the number one and three causes of death for both men and women in the U.S. Risk factors include elevated serum cholesterol, high blood pressure, a sedentary lifestyle, unhealthy diet, smoking, obesity, and hyperglycemia.

According to Mark Drucker, M.D., "Heart health is important to everyone. Remember, our hearts must be nourished to stay healthy. With protein, minerals, vitamins and fiber, Sun Chlorella is what I take, and what I recommend to all my patients."

Chlorella is a single-cell, fresh water green alga. Past research has shown that Chlorella is effective for immune activation, growth promotion, and detoxification of heavy metals and pesticides. However, unlike this recent study, most of the prior research used laboratory animals.

Dr. Randall E. Merchant earned his Doctoral and Master of Sciences degrees from the University of North Dakota. Dr. Merchant is a Professor of Anatomy and Neurosurgery at Virginia Commonwealth University, and has conducted several clinical investigations on the role of nutrition on overcoming the effects of certain chronic illnesses.

References

Toru Mizoguchi, Isao Takehara, Tohru Masuzawa, Toshiro Saito, and Yo Naoki, "Nutrigenomic Studies of Effects of Chlorella on Subjects with High-Risk Factors for Lifestyle-Related Diseases", JOURNAL OF MEDICINAL FOOD, J Med Food 11 (3) 2008, 395-404

Janet Poveromo, Aiming for the Heart to Target Cardiovascular Health Specifically Ingredient Companies are Broadening their Scope of What's Beneficial, niemagazine.com, October 2008


'/>"/>
SOURCE Randall E. Merchant, Ph.D.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Finally, a ... after venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of ... surgical procedures. , dermaka cream is very effective for bruising and causes a ...
Breaking Medicine News(10 mins):